1 / 24

Preventing recurrent TB in high HIV-prevalent areas

This article discusses the options available for TB control programs to prevent recurrent TB in high HIV-prevalent areas, including the use of RH in the continuation phase, extending the duration of CP in HIV+ patients, post-treatment isoniazid, and treating HIV+ TB patients with HAART.

karenwelch
Download Presentation

Preventing recurrent TB in high HIV-prevalent areas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preventing recurrent TB in high HIV-prevalent areas What are the options for TB Control Programmes?

  2. DEFINITION OF RECURRENT TB • TB which re-occurs after a patient has been previously diagnosed with TB and completed a full course of treatment • Bacteriologically confirmed or based on clinical criteria • Due to reactivation or reinfection

  3. EXTENT OF RECURENT TB:RESULTS OF STUDIES (1) Systematic review assessing the influence of HIV and rifampicin therapy • 47 studies world wide • 17 studies from sub-Saharan Africa (Korenromp, Scano, Williams, Dye, Nunn. Clin Inf Dis)

  4. EXTENT OF RECURENT TB:RESULTS OF STUDIES (2) Recurrent TB (rate/pa) HIV-negative 1.9% HIV-positive 4.5% 7 months or > Rifampicin 1.4% 5-6 months Rifampicin 2.0% 2-3 months Rifampicin 4.0% [level of background TB is important]

  5. EXTENT OF RECURRENT TB: REPORTS FROM NTPs AND WHOProblems • NTP annual notifications to WHO include “Relapse”, “Failure” and “Rx after DF” • WHO does not include “Failure” or “Rx after DF” in Global TB Reports • NTPs do not notify WHO about recurrent smear-negative TB or EPTB

  6. Case History: MalawiHigh HIV-prevalence countryIn 2000, 77% of TB patients HIV+ve 1990 - 1999 • 2- 4% all cases were relapse sm+ve PTB • Almost no cases of recurrent sm-ve PTB / EPTB Operational research 1999 • 12% sm-PTB /EPTB registered as “new” cases had been previously treated for TB

  7. From 1999, Malawi improved its registration of patients in terms of new and previously treated cases, especially with smear-ve PTB and EPTB

  8. Malawi Case Notifications Year Total TB New Recurrent 1998 22674 22069 605 (3%) 1999 24396 23728 668 (3%) 2000 24846 22789 2057 (8%) 2001 27672 25217 2455 (9%) 2002 26532 23724 2808 (11%) recurrent TB = relapse, failures, treatment after default plus recurrent sm-ve PTB and EPTB

  9. Why the need to reduce recurrent TB? Recurrent TB cases:- • consume resources • have a more difficult regimen • increase TB transmission in the community • cause additional morbidity and mortality • erode faith in NTP amongst patients, staff, and community

  10. Options to reduce risk of recurrence • Use RH in continuation phase (CP) • Extend duration of CP in HIV+ patients • Give post-treatment isoniazid to HIV+ve patients who complete anti-TB treatment • Treat HIV+ve TB patients with HAART

  11. For each option: • Evidence of effectiveness • Current practice • Operational considerations [consider especially for sub-Saharan Africa]

  12. RH in Continuation Phase (CP)evidence of effectiveness • Systematic review by Korenromp, Scano et al (Clin Inf Dis) • IUATLD Clinical Trial A, RH throughout has lower recurrence than EH in CP [done mainly in HIV-negative patients]

  13. RH in the CP:current practice in Africa • All programmes use RH in IP • Many programmes use EH in CP (6mo)

  14. Option:Replace EH with RH in CP for all patients The dangers: • RH needs distribution to all Rx outlets • RH must be given by DOT • Possible irrational use of RH • If H resistance high, then R as “monotherapy” • Risk of creating MDR-TB • May increase difficulties with use of HAART

  15. Extend duration of CP:evidence of effectiveness In HIV+ve patients: • 2RHZE/4RH, then 6RH recurrent TB = 1.9% • 2RHZE/4RH, then placebo recurrent TB = 9.0% (Perriens et al, NEJM 1995)

  16. Extend duration of CP:current practice in Africa Not used by any TB programme in Africa

  17. Option:Extend duration of CP for HIV+ve patients • Need knowledge of HIV-status and therefore need links with VCT • Evidence only for RH (although may work for EH) • Different lengths of Rx for HIV+ve and HIV-ve patients, and may cause confusion • Long use of RH may delay start of HAART

  18. Provide IPT to HIV+ve patients who complete treatment:evidence of effectiveness Study in Haiti HIV+ve patients: • 2RHZ/4RH, then 12H recurrent TB = 1.4% • 2RHZ/4RH, then placebo recurrent TB = 7.8% (Fitzgerald et al, Lancet 2000)

  19. Post-treatment isoniazid:current practice in Africa Not used by any TB programme in Africa

  20. Option:IPT to HIV+ve patients who complete Rx • Need knowledge of HIV-status and therefore need links with VCT • Adherence may be better than with 1o IPT • What is the optimal length of 2o IPT ? • Who administers and monitors 2o IPT ? • Will HAART obviate the need for 2o IPT?

  21. Treat HIV+ TB patients with HAART:evidence of effectiveness • In West, HAART reduces risk of TB in HIV-positive persons • In South Africa HAART reduces risk of TB in HIV-positive persons (2.4% vs 9.7% pa) [Risk reduction most in the immunocompromised] • No studies showing effect for recurrent TB

  22. HAART to HIV+ve TB patients:current practice in Africa Not used by any TB programme in Africa

  23. Option:HAART to HIV+ve patients with TB • Need knowledge of HIV-status and therefore need links with VCT • Need significant increased funding • Need a structure for safe and secure supply and delivery of HAART

  24. WAYS FORWARD • Country TB programmes to determine true burden of recurrent TB • If burden is high, then determine which of the four options is most cost-effective, feasible and least dangerous to do - • Clinical studies / operational research / philosophy of “learn as we do”

More Related